Related Experiment Video
Updated: May 19, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
IDegAsp: a novel soluble insulin analogs combination
Zhulin Ma1, Tina Parkner, Jens Sandahl Christiansen
1Aarhus University Hospital, Department of Endocrinology and Internal Medicine, Norrebrogade 44, Aarhus, 8000, Denmark. joli.mzl@gmail.com
Expert Opinion on Biological Therapy
|September 6, 2012
Summary
IDegAsp, a novel insulin combination, offers similar glycemic control to existing options with a reduced risk of hypoglycemia. This insulin therapy shows promise for type 2 diabetes management.
Area of Science:
- Diabetes Mellitus Research
- Pharmacology
- Endocrinology
Background:
- Co-formulation of rapid- and long-acting insulins presents pharmacokinetic challenges.
- Insulin degludec aspart (IDegAsp) is a novel soluble combination of rapid-acting insulin aspart and ultra-long-acting insulin degludec.
- IDegAsp was developed to potentially improve upon existing premixed insulin suspensions.
Purpose of the Study:
- To review and summarize the pharmacological characteristics, clinical efficacy, safety, and tolerability of IDegAsp.
- To assess the potential clinical advantages of IDegAsp compared to current insulin preparations.
Main Methods:
- A comprehensive literature review was conducted.
- Published data on IDegAsp were searched through PubMed, EMBASE, and Web of Knowledge up to June 2012.
- The review focused on pharmacological profiles, clinical outcomes, and safety data.
Main Results:
- Preliminary clinical data suggest IDegAsp is safe and well-tolerated.
- IDegAsp demonstrates comparable overall glycemic control to existing insulin preparations.
- A reduced risk of hypoglycemia was observed with IDegAsp.
Conclusions:
- IDegAsp represents a promising treatment option for type 2 diabetes.
- It may be particularly beneficial for patients requiring improved control of both postprandial and fasting glucose levels.
- The combination offers a potentially safer alternative with similar efficacy to current insulin therapies.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...